Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer By Ogkologos - July 15, 2025 662 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POD1UM-303/InterAACT-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with... December 12, 2024 Using Integrative Therapies to Help Manage Cancer-Related Pain: An Expert Q&A July 20, 2023 Malaria Vaccine Approved by W.H.O. Could Save Tens Of Thousands Of... October 7, 2021 COVID-19: “We’re having to rebuild and adapt because of coronavirus” July 15, 2020 Load more HOT NEWS Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... Palliative and Supportive Care for Children With Cancer: An Expert Perspective EMA Recommends Granting a Marketing Authorisation for Fruquintinib Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer
